Elizabeth E. Morgan

1.4k total citations
18 papers, 557 citations indexed

About

Elizabeth E. Morgan is a scholar working on Immunology, Pharmacology and Molecular Medicine. According to data from OpenAlex, Elizabeth E. Morgan has authored 18 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Pharmacology and 5 papers in Molecular Medicine. Recurrent topics in Elizabeth E. Morgan's work include Antibiotics Pharmacokinetics and Efficacy (6 papers), Immunotherapy and Immune Responses (5 papers) and Antibiotic Resistance in Bacteria (5 papers). Elizabeth E. Morgan is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (6 papers), Immunotherapy and Immune Responses (5 papers) and Antibiotic Resistance in Bacteria (5 papers). Elizabeth E. Morgan collaborates with scholars based in United States, Australia and United Kingdom. Elizabeth E. Morgan's co-authors include Jeffery S. Loutit, Michael N. Dudley, David C. Griffith, Dennis J. Carlo, David E. Geller, Patrick A. Flume, Stephanie Durso, Steven P. Richieri, Steven W. Brostoff and Arthur A. Vandenbark and has published in prestigious journals such as Annals of the New York Academy of Sciences, Antimicrobial Agents and Chemotherapy and Journal of Neuroimmunology.

In The Last Decade

Elizabeth E. Morgan

18 papers receiving 527 citations

Peers

Elizabeth E. Morgan

PRM

IMMUN

PHARM

EPIDE

K. Ramachandran India

A Florio Italy

Sei Jin Youn South Korea

Idan Goren Israel

M. Quitadamo Italy

S Chung Hong Kong

Kazufumi Yamagata Japan

Eisuke Suganuma Japan

Hiroki Tanaka Japan

K. Ramachandran India

Elizabeth E. Morgan

75 ×0.5

PRM

42 ×0.3

IMMUN

12 ×0.1

28 ×0.2

PHARM

71 ×0.7

EPIDE

Citations per year, relative to Elizabeth E. Morgan Elizabeth E. Morgan (= 1×) peers K. Ramachandran

Countries citing papers authored by Elizabeth E. Morgan

Since Specialization

Citations

This map shows the geographic impact of Elizabeth E. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth E. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth E. Morgan more than expected).

Fields of papers citing papers by Elizabeth E. Morgan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth E. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth E. Morgan. The network helps show where Elizabeth E. Morgan may publish in the future.

Co-authorship network of co-authors of Elizabeth E. Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth E. Morgan. A scholar is included among the top collaborators of Elizabeth E. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth E. Morgan. Elizabeth E. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wallis, Steven C., Elizabeth E. Morgan, Michael N. Dudley, et al.. (2023). A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects. Antimicrobial Agents and Chemotherapy. 68(1). e0109923–e0109923. 1 indexed citations

Griffith, David C., Elizabeth E. Morgan, Michael N. Dudley, & Jeffery S. Loutit. (2021). Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 65(5). 6 indexed citations

Cornely, Oliver A., Dorothee Arenz, Olivier Barraud, et al.. (2018). 1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects. Open Forum Infectious Diseases. 5(suppl_1). S425–S426. 5 indexed citations

Rubino, Christopher M., Sujata M. Bhavnani, Jeffery S. Loutit, et al.. (2018). Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 62(4). 46 indexed citations

Flume, Patrick A., Donald R. VanDevanter, Elizabeth E. Morgan, et al.. (2016). A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis. 15(4). 495–502. 54 indexed citations

Griffith, David C., Jeffery S. Loutit, Elizabeth E. Morgan, Stephanie Durso, & Michael N. Dudley. (2016). Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 60(10). 6326–6332. 63 indexed citations

Elborn, J.S., David E. Geller, Douglas Conrad, et al.. (2015). A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis. 14(4). 507–514. 55 indexed citations

Griffith, David E., et al.. (2014). 401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects. Open Forum Infectious Diseases. 1(suppl_1). S154–S155. 10 indexed citations

Stickney, Dwight R., et al.. (2011). Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.. PubMed. 3(3). 275–83. 4 indexed citations

10.

Geller, David E., Patrick A. Flume, David C. Griffith, et al.. (2011). Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects. Antimicrobial Agents and Chemotherapy. 55(6). 2636–2640. 63 indexed citations

11.

Offner, Halina, Alex Zamora, Agata Matejuk, et al.. (2002). A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing–remitting EAE. Journal of Neuroimmunology. 130(1-2). 128–139. 38 indexed citations

12.

Morgan, Elizabeth E., Christopher Nardo, Jocelyn P. Diveley, et al.. (2001). Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide‐specific T‐cell responses in patients with multiple sclerosis. Journal of Neuroscience Research. 64(3). 298–301. 19 indexed citations

13.

Vandenbark, Arthur A., Elizabeth E. Morgan, Richard M. Bartholomew, et al.. (2001). TCR Peptide Therapy in Human Autoimmune Diseases. Neurochemical Research. 26(6). 713–730. 40 indexed citations

14.

Moreland, Larry W., Elizabeth E. Morgan, T. C. Adamson, et al.. (1998). T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides. Arthritis & Rheumatism. 41(11). 1919–1929. 57 indexed citations

15.

Moreland, Larry W., Elizabeth E. Morgan, T. C. Adamson, et al.. (1998). T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V3, V14, and V17 Peptides. Arthritis & Rheumatism. 41(11). 1919–1929. 1 indexed citations

16.

Gold, Daniel P., Richard Smith, Elizabeth E. Morgan, et al.. (1997). Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. Journal of Neuroimmunology. 76(1-2). 29–38. 50 indexed citations

17.

Moreland, Larry W., Louis W. Heck, William J. Koopman, et al.. (1996). V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study.. PubMed. 23(8). 1353–62. 34 indexed citations

18.

Moreland, Larry W., Louis W. Heck, William J. Koopman, et al.. (1995). Vβ17 T‐Cell Receptor Peptide Vaccine. Annals of the New York Academy of Sciences. 756(1). 211–214. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact